Sampre Nutritions Reports Q2 Profit, Approves Equity Share Issuance to Promoters

Sampre Nutritions Limited , a key player in the nutritional products sector, has reported a profitable second quarter for the fiscal year 2025-26 and announced plans for equity share issuance to its promoters. The company's Board of Directors approved both standalone and consolidated unaudited financial results for Q2 and H1 FY2025-26, along with a significant move to convert existing unsecured loans into equity.

Financial Performance

For the quarter ended September 30, 2025, Sampre Nutritions reported the following key financial metrics on a standalone basis:

Particulars (in ₹ lakhs)	Q2 FY2025-26	H1 FY2025-26
Revenue from Operations	999.74	2,086.39
Total Revenue	1,000.28	2,089.43
Total Expenses	894.13	1,912.34
Profit Before Tax	106.15	177.09
Net Profit	89.47	160.41

The company's performance shows a significant improvement compared to the same period last year, with a substantial increase in both revenue and profitability.

Equity Share Issuance

In a strategic move, the Board of Directors has approved the issuance of equity shares to promoters through the conversion of existing unsecured loans. The key details of this preferential allotment are:

Number of shares to be issued: 1,770,710 equity shares
Face value: ₹5 per share
Issue price: ₹42 per share
Total value of conversion: Approximately ₹7.44 crore

The beneficiaries of this allotment are:

Brahma Gurbani: To receive 1,693,880 shares
Meera Gurbani: To receive 76,830 shares

This move is expected to strengthen the company's balance sheet by reducing debt and increasing equity capital.

Impact on Shareholding Structure

Post-allotment, the shareholding structure of the promoters will change as follows:

Promoter	Pre-Issue Shares	Pre-Issue %	Post-Issue Shares	Post-Issue %
Brahma Gurbani	5,549,664	6.35%	7,243,544	8.12%
Meera Gurbani	3,283,048	3.76%	3,359,878	3.77%

The company plans to convene an Extraordinary General Meeting to obtain member approval for this preferential allotment.

Sampre Nutritions' strong financial performance and strategic capital restructuring indicate the company's focus on growth and financial stability. Investors and stakeholders will be keenly watching how these moves translate into long-term value creation for the company.

Note: All financial figures are based on standalone results unless otherwise specified.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.97%	-9.53%	+12.13%	+463.26%	+81.93%	+1,416.82%

Sampre Nutritions Limited has announced a revision to the record date for its upcoming stock split and bonus issue of equity shares. This corporate action, aimed at rewarding shareholders, has seen a slight delay in its timeline.

Key Details of the Revised Corporate Action

Aspect	Original Date	Revised Date
Record Date	November 4, 2025	November 11, 2025
Deemed Allotment Date	-	November 12, 2025
Bonus Shares Allotted	-	43,693,710
Depository Credit Deadline	-	November 12, 2025 (12:00 PM)
Trading Availability	-	November 13, 2025

Implications for Shareholders

The company has confirmed that the bonus shares will be credited to the depository system by noon on November 12, 2025, ensuring that they are available for trading from November 13, 2025. This move allows shareholders an additional week to position themselves for the corporate action.

Regulatory Compliance

In its communication to the BSE, Sampre Nutritions emphasized its compliance with SEBI Circular SEBI/CIR/CFD/PoD/2024/122 dated September 16, 2024. The company has provided a Demat Request Number (DNR) range from 1 to 87,387,420 for the bonus issue.

Management Statement

Brahma Gurbani, Managing Director of Sampre Nutritions Limited, signed off on the regulatory filing, underlining the company's commitment to transparency and adherence to listing regulations.

This revision in the record date demonstrates Sampre Nutritions' attention to detail in executing corporate actions and ensures that shareholders have ample time to prepare for the upcoming changes in their holdings.